Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 309 000 KRW 4.04% Market Closed
Market Cap: 16.5T KRW
Have any thoughts about
Alteogen Inc?
Write Note

Alteogen Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alteogen Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Accrued Liabilities
â‚©466.4m
CAGR 3-Years
23%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Accrued Liabilities
â‚©205.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Accrued Liabilities
â‚©19.7B
CAGR 3-Years
20%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Accrued Liabilities
â‚©64.9B
CAGR 3-Years
-9%
CAGR 5-Years
4%
CAGR 10-Years
7%
H
Hugel Inc
KOSDAQ:145020
Accrued Liabilities
â‚©2.2B
CAGR 3-Years
-12%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Accrued Liabilities
â‚©1.4B
CAGR 3-Years
28%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
16.4T KRW
Industry
Biotechnology

Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.

Intrinsic Value
33 513.79 KRW
Overvaluation 89%
Intrinsic Value
Price

See Also

What is Alteogen Inc's Accrued Liabilities?
Accrued Liabilities
466.4m KRW

Based on the financial report for Sep 30, 2024, Alteogen Inc's Accrued Liabilities amounts to 466.4m KRW.

What is Alteogen Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
42%

Over the last year, the Accrued Liabilities growth was 28%. The average annual Accrued Liabilities growth rates for Alteogen Inc have been 23% over the past three years , 42% over the past five years .

Back to Top